• Astellas slated 21 oncology abstracts for ESMO 2026 in Madrid on Oct. 23-27, led by updates for PADCEV with pembrolizumab.
• Results will be presented at the meeting, featuring the longest follow-up yet for the regimen in advanced bladder cancer.
• Data aim to reinforce a durable survival benefit, supporting the combination’s role in first-line treatment decisions.
• Pipeline readouts will also outline late-stage setidegrasib trials in KRAS G12D pancreatic cancer, KRAS G12D lung cancer.
• Earlier studies include ASP546C in CLDN18.2-expressing tumors, ASP5834 in KRAS-altered tumors, signaling continued investment in hard-to-treat cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astellas Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610061930PR_NEWS_USPR_____CG65130) on October 06, 2026, and is solely responsible for the information contained therein.